Adherence of Patients to the Antihypertensive Treatment in Georgian Population
Por: D. Trapaidze MD., B. Tsinamdzgvrishvili MD, PhD., R. Tataradze MD, PhD., L. Sturua MD, PhD, MPH., T. Abesadze MD.y A. Rekhviashvili MD. 6VCC > High Blood Pressure. (September – November/2009)
Hypertension is a common, chronic disorder which is associated with a significant risk for cardiovascular diseases. Current guidelines emphasise that lowering elevated blood pressure (BP) reduced morbidity from stroke, myocardial infarction, congestive heart failure and renal failure. This inadequate control not only has significant consequences in terms of patient morbidity and mortality, but also in terms of health care costs.
Poor compliance with antihypertensive therapy is thought to be a major factor in the failure to control hypertension. Between 30% and 46% of patients may be non compliant with their antihypertensive drug regimens.
There has been much debate concerning the causes of noncompliance with antihypertensive therapy. Major factors are thought to be asymptomatic nature of hypertension, unacceptable side effects of therapy, suboptimal antihypertensive efficacy, and lack of effective communication between clinician and patient. [Actualizado: 11 de junio de 2013]
The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review
Por: Anastasia G Ptinopoulou, Maria I Pikilidou y Anastasios N Lasaridis. Hypertension Research (2013) 36, 91–101.
Data from randomized clinical trials and epidemiological evidence identify systemic hypertension as the second most common modifiable risk factor for chronic kidney disease (CKD) progression after diabetes mellitus. CKD may progress silently over the years and early diagnosis and control of hypertension is of major importance in delaying renal function decline. Recent guidelines for the treatment of hypertension suggest the use of a variety of antihypertensive drugs in order to achieve the desired blood pressure levels. Renin–angiotensin system inhibitors have been undoubtedly studied the most and are suggested by guidelines and experts as first choice in patients with hypertension and renal injury, particularly in those with diabetes, as they have repeatedly shown to significantly reduce proteinuria. [Actualizado: 20 de mayo 2013]
Por: Ihab Hajjar, Meaghan Hart, William Milberg, Vera Novak, y Lewis Lipsitz. BMC Geriatrics 2009, 9:48.
Nuestro objetivo es llevar a cabo un estudio doble ciego aleatorizado ensayo clínico controlado con antihipertensivos y función vascular endotelial y cognitiva (AVEC), para comparar un tratamiento de 3 años con antihipertensivos (lisinopril, candesartán o hidroclorotiazida) y su efecto sobre la memoria y la función ejecutiva, el flujo sanguíneo cerebral y la función endotelial centro de personas mayores con hipertensión arterial y pruebas objetivas precoz de las deficiencias ejecutivas o de memoria.
Investigaciones expone trabajos que pueden aún no tener evidencias suficientes por su actualidad.
Por: Ji Young Park, Jung Wook Yun, Young Whan Choi, Jin Ung Bae, Kyo Won Seo, Seung Jin Lee, So Youn Park, Ki Whan Hong y Chi Dae Kim. Hypertension Research (2012) 35, 928–934.
These alterations in BP, NOS phosphorylation and ROS production in the vasculature of Ang II-treated mice were markedly and dose-dependently reversed by simultaneous administration of GA (2 and 10μg kg−1 per min). In addition, Ang II-induced ROS production in cultured vascular cells such as endothelial cells and vascular smooth muscle cells was markedly attenuated by GA. These results suggested that GA attenuated the increase in BP via preservation of vascular NO bioavailability not only by inhibiting ROS production but also by preventing the impairment of eNOS function in the vasculature of Ang II-induced hypertensive mice.
Comentarios recientes